UCB Stock Analysis: UCB | BR
Biotechnology | BR, Belgium | Market Cap: 45.553m EUR | 12M Return: 38.1% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 43.7M
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
UCB SA is a Belgium-based biopharmaceutical company founded in 1925 and headquartered in Brussels, listed on the Brussels exchange as a large-cap health care stock. The company focuses on developing and commercializing therapies for neurology and immunology diseases, with a global commercial footprint and an additional contract manufacturing business.
Its marketed portfolio spans multiple therapeutic areas. In neurology, UCB offers Vimpat, Keppra, and Briviact for epilepsy, Neupro for Parkinsons disease and restless legs syndrome, Nayzilam for seizure clusters, Fintepla for Dravet and Lennox-Gastaut syndromes, and RYSTIGGO and ZILBRYSQ for generalized myasthenia gravis. In immunology, Cimzia is approved for conditions including ankylosing spondylitis, Crohns disease, rheumatoid arthritis, and plaque psoriasis, while Bimzelx targets plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis. The company also markets Evenity for postmenopausal osteoporosis and the consumer allergy brands Zyrtec and Xyzal.
The pipeline reflects continued investment in rare neurological and immune-mediated disorders, including KYGEVVI for thymidine kinase 2 deficiency, dapirolizumab pegol for systemic lupus erythematosus, STACCATO alprazolam for prolonged seizures, bepranemab for Alzheimers disease, and UCB9741 for atopic dermatitis, non-cystic fibrosis bronchiectasis, and COPD. As a research-driven biopharma, UCBs business model relies on patent-protected branded biologics and small molecules, late-stage pipeline progression, and lifecycle management across neurology and immunology franchises.
- Bimzelx sales surge offset Vimpat and Keppra generic erosion
- Evenity and RYSTIGGO launches diversify revenue beyond mature franchises
- Bepranemab Alzheimers readout creates major pipeline binary event
| Net Income: 1.56b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA 5.18 > 1.0 |
| NWC/Revenue: 21.35% < 20% (prev 20.46%; Δ 0.89% < -1%) |
| CFO/TA 0.12 > 3% & CFO 2.16b > Net Income 1.56b |
| Net Debt (-43.0m) to EBITDA (1.79b): -0.02 < 3 |
| Current Ratio: 1.38 > 1.5 & < 3 |
| Outstanding Shares: last quarter (190.0m) vs 12m ago -4.82% < -2% |
| Gross Margin: 74.29% > 18% (prev 69.64%; Δ 4.66% > 0.5%) |
| Asset Turnover: 43.61% > 50% (prev 35.46%; Δ 8.14% > 0%) |
| Interest Coverage Ratio: 5.63 > 6 (EBIT TTM 1.17b / Interest Expense TTM 207.0m) |
| A: 0.09 (Total Current Assets 6.05b - Total Current Liabilities 4.40b) / Total Assets 18.2b |
| B: 0.48 (Retained Earnings 8.68b / Total Assets 18.2b) |
| C: 0.07 (EBIT TTM 1.17b / Avg Total Assets 17.8b) |
| D: 1.49 (Book Value of Equity 10.9b / Total Liabilities 7.29b) |
| Altman-Z'' = 4.16 = AA |
| DSRI: 1.08 (Receivables 1.79b/1.31b, Revenue 7.74b/6.15b) |
| GMI: 0.94 (GM 69.64% / 74.29%) |
| AQI: 0.90 (AQ_t 0.56 / AQ_t-1 0.62) |
| SGI: 1.26 (Revenue 7.74b / 6.15b) |
| TATA: -0.03 (NI 1.56b - CFO 2.16b) / TA 18.2b) |
| Beneish M = -2.89 (Cap -4..+1) = A |
As of July 28, 2026, the stock is trading at EUR 245.80 with a total of 136,709 shares traded. Over the past week, the price has changed by +3.28%, over one month by -6.72%, over three months by +3.78% and over the past year by +38.05%.
Current recommended Stop Loss: 236.70 (which is 3.7% or 1.3 ATR below the current price).
UCB has no consensus analysts rating.
P/E Trailing = 29.7637
P/E Forward = 22.7273
P/S = 6.0028
P/B = 4.1919
P/EG = 1.8172
Revenue TTM = 7.74b EUR
EBIT TTM = 1.17b EUR
EBITDA TTM = 1.79b EUR
Long Term Debt = 2.06b EUR (from longTermDebt, last quarter)
Short Term Debt = 62.0m EUR (from shortTermDebt, last quarter)
Debt = 2.43b EUR (from shortLongTermDebtTotal, last quarter) + Leases 182.0m
Net Debt = -43.0m EUR (calculated: Debt 2.43b - CCE 2.47b)
Enterprise Value = 45.5b EUR (45.6b + Debt 2.43b - CCE 2.47b)
Interest Coverage Ratio = 5.63 (Ebit TTM 1.17b / Interest Expense TTM 207.0m)
EV/FCF = 23.29x (Enterprise Value 45.5b / FCF TTM 1.95b)
FCF Yield = 4.29% (FCF TTM 1.95b / Enterprise Value 45.5b)
FCF Margin = 25.24% (FCF TTM 1.95b / Revenue TTM 7.74b)
Net Margin = 20.13% (Net Income TTM 1.56b / Revenue TTM 7.74b)
Gross Margin = 74.29% ((Revenue TTM 7.74b - Cost of Revenue TTM 1.99b) / Revenue TTM)
Gross Margin QoQ = 74.89% (prev 73.56%)
Tobins Q-Ratio = 2.51 (Enterprise Value 45.5b / Total Assets 18.2b)
Interest Expense / Debt = 8.53% (Interest Expense 207.0m / Debt 2.43b)
Taxrate = 14.49% (264.0m / 1.82b)
NOPAT = 997.1m (EBIT 1.17b * (1 - 14.49%))
Current Ratio = 1.38 (Total Current Assets 6.05b / Total Current Liabilities 4.40b)
Debt / Equity = 0.22 (Debt 2.43b / totalStockholderEquity, last quarter 10.9b)
Debt / EBITDA = -0.02 (Net Debt -43.0m / EBITDA 1.79b)
Debt / FCF = -0.02 (Net Debt -43.0m / FCF TTM 1.95b)
Total Stockholder Equity = 9.88b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.78% (Net Income 1.56b / Total Assets 18.2b)
RoE = 15.76% (Net Income TTM 1.56b / Total Stockholder Equity 9.88b)
RoCE = 9.76% (EBIT 1.17b / Capital Employed (Equity 9.88b + L.T.Debt 2.06b))
RoIC = 7.42% (NOPAT 997.1m / Invested Capital 13.4b)
WACC = 7.20% (E(45.6b)/V(48.0b) * Re(7.19%) + D(2.43b)/V(48.0b) * Rd(8.53%) * (1-Tc(0.14)))
Discount Rate = 7.19% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -20.15 | Cagr: -1.02%
[DCF] Terminal Value 77.97% ; FCFF base≈1.56b ; Y1≈1.79b ; Y5≈2.63b
[DCF] Fair Price = 208.3 (EV 39.6b - Net Debt -43.0m = Equity 39.6b / Shares 190.4m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: 96.51 | Revenue CAGR: 18.19% | SUE: 0.06 | # QB: 0
EPS current Year (2026-12-31): EPS=10.87 | Chg30d=+0.83% | Revisions=-10% | GrowthEPS=+8.8% | GrowthRev=+10.4%
EPS next Year (2027-12-31): EPS=13.60 | Chg30d=-0.14% | Revisions=-30% | GrowthEPS=+25.1% | GrowthRev=+12.9%
[Analyst] Revisions Ratio: -24% (up=5, down=9)